U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07735377) titled 'A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer' on July 24.
Brief Summary: This is a phase 1 study to assess the safety and tolerability of SHR-6914 as monotherapy therapy in adult subjects with prostate cancer.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: SHR-6914
SHR-6914
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily ...